Trevi Therapeutics, Inc. (TRVI) Financial Analysis & Valuation | Quarter Chart

Trevi Therapeutics, Inc. (TRVI)

TRVI
Price: $13.82
Fair Value: 🔒
🔒score
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clin... more
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and... more
Description Shares
Market Cap$1.94BExchangeNASDAQ
SectorHealthcareIndustryBiotechnology
CountryUSCEOJennifer L. Good
IPO Date2019-05-07CAGR
Employees31Websitewww.trevitherapeutics.com
Div. YieldPayout Ratio
Buy Back YieldTotal Yield
TRVI chart loading...
Fundamentals Technicals
Enterprise Value$2.37BP/E Ratio-43.19
Forward P/E-24.46PEG Ratio
P/S RatioP/B Ratio2123.55
P/CF Ratio-9225.94P/FCF Ratio-11994.45
EPS$-0.32EPS Growth 1Y-32.02%
EPS Growth 3Y-42.55%EPS Growth 5Y-82.35%
Revenue Growth 1YGross Margin
Operating MarginProfit Margin
ROE-0.27%ROA-0.24%
ROCE-0.28%Current Ratio19.66
Quick Ratio19.66Cash Ratio1.94
Debt/Equity0Interest Coverage-51351
Altman Z Score115.75Piotroski Score2